Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There is a lack of contemporary population-based data on the epidemiology of acute promyelocytic leukemia (APL) in the United States. In this study, we aim to elucidate the demographics and early mortality patterns of APL hospitalizations utilizing the National Inpatient Sample database from 2016–2019. APL's annual age-adjusted incidence rate was 0.28/100,000, and the incidence increased with age, with the peak incidence in the 75–79 age group at 0.62/100,000. Whites constituted the majority of admissions at 67.7%, followed by Hispanics at 15.3%, the youngest racial group with a median age of 40 years. The median length of stay was 31 days for patients age < 60 years and 25 days for age ≥ 60 years (p < 0.001). After adjusting for confounders, the mean length of stay was 7 days higher in teaching hospitals compared to non-teaching hospitals (p 0.001). Overall mortality was 12.1% (22.2% for age ≥ 60 and 6.4% for < 60 years {p < 0.001}), and 56.5% of deaths happened before 7 days, with the median time to death being 6 days. The proportion of early deaths (< 7 days) in non-teaching hospitals was higher than late deaths (≥ 7 days) (19.2% vs. 5%; p 0.03), and admission to a teaching hospital was associated with lower mortality (adjusted odds ratio 0.27; p 0.01). Therefore, optimal treatment strategies need to be explored to mitigate this significant early mortality, especially in non-teaching hospitals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data that support the findings of this study are available upon request.

References

  1. Rizzatti EG, Garcia AB, Portieres FL, Silva DE, Martins SL, Falcao RP (2002) Expression of CD117 and CD11b in bone marrow can differentiate acute promyelocytic leukemia from recovering benign myeloid proliferation. Am J Clin Pathol 118(1):31–37. https://doi.org/10.1309/6U82-2WNG-4KX3-HBMA

    Article  CAS  PubMed  Google Scholar 

  2. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF (1973) Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41(4):489–496

    Article  CAS  PubMed  Google Scholar 

  3. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Roman J, Barragan E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P, Programa de Estudio y Traitmiento de las Hemopatias M (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103(4):1237-1243. https://doi.org/10.1182/blood-2003-07-2462

  4. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D, Group UKNCRIAMLW (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16 (13):1295-1305. https://doi.org/10.1016/S1470-2045(15)00193-X

  5. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF, Australasian L, Lymphoma G (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120(8):1570–1580; quiz 1752. https://doi.org/10.1182/blood-2012-02-410746

  6. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ (2018) Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol 19(7):871–879. https://doi.org/10.1016/S1470-2045(18)30295-X

    Article  CAS  PubMed  Google Scholar 

  7. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F, Takeshita A, Kimura Y, Iwanaga M, Naoe T, Ohno R, Japan Adult Leukemia Study G (2007) A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110(1):59-66. https://doi.org/10.1182/blood-2006-08-043992

  8. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dA, German-Austrian Acute Myeloid Leukemia Study G, Study Alliance L (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111-121. https://doi.org/10.1056/NEJMoa1300874

  9. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F (2012) Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer 118(23):5811–5818. https://doi.org/10.1002/cncr.27623

    Article  PubMed  Google Scholar 

  10. Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, Aksu S, Ozcebe OI, Turgut M, Aslan R, Ozdemir E (2010) Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res 34(12):e317-319. https://doi.org/10.1016/j.leukres.2010.07.027

    Article  PubMed  Google Scholar 

  11. Jacomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, Bittencourt HN, Bittencourt RI, Bortolheiro TC, Paton EJ, Bendlin R, Ismael S, Chauffaille Mde L, Silva D, Pagnano KB, Ribeiro R, Rego EM (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92(10):1431–1432. https://doi.org/10.3324/haematol.10874

    Article  PubMed  Google Scholar 

  12. Jillella AP, Kota VK (2018) The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia. Blood Rev 32(2):89–95. https://doi.org/10.1016/j.blre.2017.09.001

    Article  CAS  PubMed  Google Scholar 

  13. Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Muller-Tidow C, Wormann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Buchner T, German Acute Myeloid Leukemia Cooperative G (2013) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 92(1):41-52. https://doi.org/10.1007/s00277-012-1597-9

  14. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118(5):1248–1254. https://doi.org/10.1182/blood-2011-04-346437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stas Kolenikov (2022) Programs and tutorials written by Stas Kolenikov. Accessed 25 Aug 2022

  16. Dinmohamed AG, Visser O (2019) Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem Cell Investig 6:37. https://doi.org/10.21037/sci.2019.10.03

    Article  PubMed  PubMed Central  Google Scholar 

  17. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, Derolf AR, Stockelberg D, Tidefelt U, Wahlin A, Wennstrom L, Hoglund M, Juliusson G (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 25(7):1128–1134. https://doi.org/10.1038/leu.2011.78

    Article  CAS  PubMed  Google Scholar 

  18. U.S. Census Bureau Releases (2019) Population Estimates by Demographic Characteristics. https://www.census.gov/newsroom/press-releases/2020/65-older-population-grows.html#:~:text=In%202019%2C%20the%20median%20age%20for%20the%20Hispanic%20population%20was,population%20between%202018%20and%202019. Accessed August 25, 2022

  19. Profile: Hispanic/Latino Americans. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=3&lvlid=64. Accessed August 25, 2022

  20. Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 15(4):367–370. https://doi.org/10.1097/00008469-200608000-00011

    Article  Google Scholar 

  21. Keung YK, Chen SC, Groshen S, Douer D, Levine AM (1994) Acute myeloid leukemia subtypes and response to treatment among ethnic minorities in a large US urban hospital. Acta Haematol 92(1):18–22. https://doi.org/10.1159/000204131

    Article  CAS  PubMed  Google Scholar 

  22. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM (1996) High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 87(1):308–313

    Article  CAS  PubMed  Google Scholar 

  23. Douer D, Santillana S, Ramezani L, Samanez C, Slovak ML, Lee MS, Watkins K, Williams T, Vallejos C (2003) Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. Br J Haematol 122(4):563–570. https://doi.org/10.1046/j.1365-2141.2003.04480.x

    Article  CAS  PubMed  Google Scholar 

  24. Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nunez V, Gomez-Rangel JD, Ruiz-Delgado GJ (2004) More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 45(7):1365–1368. https://doi.org/10.1080/10428190310001657344

    Article  CAS  PubMed  Google Scholar 

  25. Hales CM, Fryar CD, Carroll MD, Freedman DS, Aoki Y, Ogden CL (2018) Differences in Obesity Prevalence by Demographic Characteristics and Urbanization Level Among Adults in the United States, 2013–2016. JAMA 319(23):2419–2429. https://doi.org/10.1001/jama.2018.7270

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tedesco J, Qualtieri J, Head D, Savani BN, Reddy N (2011) High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic Syndrome. Ther Adv Hematol 2(3):141–145. https://doi.org/10.1177/2040620711408490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M (1997) Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 11(10):1661–1664. https://doi.org/10.1038/sj.leu.2400783

    Article  CAS  PubMed  Google Scholar 

  28. Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Mahmud S, Meloche C, Sabloff M, Sharif I, Storring J, Turner D, Seftel MD (2014) Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 166(5):660–666. https://doi.org/10.1111/bjh.12931

    Article  PubMed  Google Scholar 

  29. Jillella AP, Arellano ML, Gaddh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK (2021) Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. JCO Oncol Pract 17(4):e497–e505. https://doi.org/10.1200/OP.20.00395

    Article  PubMed  Google Scholar 

  30. Evans GD, Grimwade DJ (1999) Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 33(3–4):219–229. https://doi.org/10.3109/10428199909058422

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Karmanos Cancer Institute/Wayne State University School of Medicine, 4100 John R, HW04H0, Detroit, MI, 48201, USA

    Aditi Sharma, Jay Yang & Vijendra Singh

Authors
  1. Aditi Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vijendra Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditi Sharma.

Ethics declarations

Declarations

Poster presented at SOHO (Society of Hematologic Oncology) 2022 and abstract was published in Clinical Lymphoma Myeloma and Leukemia on 10/1/2022, volume 22, Pages S218-S219.

Financial disclosure

The authors have no existing or potential financial conflict of interest to disclose.

Conflict of interest

No relevant conflict of interest exists.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 20 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Yang, J. & Singh, V. Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States. Ann Hematol 102, 1053–1062 (2023). https://doi.org/10.1007/s00277-023-05154-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05154-0

Keywords

Search

Navigation